WINDLAS BIOTECH LIMITED
Latest filings
- Independent Director Mr Vivek Dhariwal resigns effective Oct 12, 2026 · Management Changes
- Board changes: two new independent directors join, one resigns · Management Changes
- Windlas Biotech appoints two independent directors, one resigns · Management Changes
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures pharmaceutical formulations on contract for other pharma companies (CDMO), sells trade generics and institutional products in India, and exports formulations to regulated and emerging markets. The CDMO vertical is the dominant business at ₹664 crores in FY26 (+20% Y-o-Y), supplying contract development and manufacturing services to a diversified client base. Trade Generics and Institutional sales contributed ₹195 crores (+13%), while Exports grew 40% to ₹46 crores with Philippines GMP received for Plants 4 and 5 (injectables). Plant 6 reached mechanical completion and is targeted for H1 FY27 commercialisation, with a further 10–15% efficiency upside targeted on top of existing manufacturing capacity that will also include ₹100 crores of injectable capacity. Employee costs at 16.8% of revenue are the largest disclosed cost line; capex is at 7.5% of revenue with FY27 planned as maintenance capex only. The injectable facility has GLP-1 vial-filling capability being evaluated for CDMO opportunities, and Q4 FY26 was the 13th consecutive quarter of record revenue.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Nothing flagged in the filed numbers.Charts
How has the market priced it — with filings on the timeline?
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from WINDLAS BIOTECH LIMITED's filed financials and exchange disclosures
What does WINDLAS BIOTECH LIMITED do?
WINDLAS BIOTECH LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol WINDLAS.
Is WINDLAS BIOTECH LIMITED profitable?
Yes. Over the trailing twelve months WINDLAS BIOTECH LIMITED reported a net profit of ₹66 Cr on revenue of ₹904 Cr.
Does WINDLAS BIOTECH LIMITED pay a dividend?
Yes. The dividend yield is 0.67% at the current price. It paid out 18% of its profit as dividend in FY26.
Is WINDLAS BIOTECH LIMITED debt-free?
No. It reported borrowings of ₹30 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹29 Cr after cash. Debt stands at 0.05× equity. That is lower than 59% of its 166 Pharmaceuticals peers.
Is WINDLAS BIOTECH LIMITED expensive compared with its peers?
On trailing P/E, WINDLAS BIOTECH LIMITED ranks 74 of 158 in Pharmaceuticals — cheaper than 54% of them, against an industry median of 30.1×. This is a position, not a valuation judgement.
How much does the WINDLAS BIOTECH LIMITED share price move in a day?
On a typical session WINDLAS BIOTECH LIMITED moves 1.23% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
Where can I track WINDLAS BIOTECH LIMITED's announcements?
Every NSE and BSE filing by WINDLAS BIOTECH LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.